☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - September 2021

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of September 2021. This month is one technology appraisal and one COVID-19 rapid guideline that impact upon primary care.

The Sapropterin for treating hyperphenylalaninaemia in phenylketonuria technology appraisal has been published. This treatment is recommended as an option for treating hyperphenylalaninaemia that responds to sapropterin (response as defined in the summary of product characteristics) in people with phenylketonuria (PKU), only if they are:

  • under 18 and a dose of 10 mg/kg is used, only using a higher dose if target blood phenylalanine levels cannot be achieved at 10 mg/kg
  • aged 18 to 21 inclusive, continuing the dose they were having before turning 18 or at a maximum dose of 10 mg/kg
  • pregnant (from a positive pregnancy test until birth).

It is also noted that sapropterin is recommended only if the company provides it according to the commercial arrangement. It would be expected that treatment would be commenced and supervised by a specialist.

The COVID-19 rapid guideline: managing COVID-19 guideline has been updated. The update this month adds new recommendations on non-invasive respiratory support and doxycycline, and updated recommendations on heparins. Specifically for primary care it is recommended that doxycycline is not used to treat COVID-19 in the community.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - September 2021' on Email Share 'NICE Guidance - September 2021' on Delicious Share 'NICE Guidance - September 2021' on Digg Share 'NICE Guidance - September 2021' on Facebook Share 'NICE Guidance - September 2021' on reddit Share 'NICE Guidance - September 2021' on Twitter

CKS Updates - August 2021

During August 2021 Clinical Knowledge Summaries were updated in the following areas.

All topics have been reviewed and updated in keeping with current guidance with minor layout changes. The Carpal tunnel syndrome recommendations on follow up in primary care have been amended to reflect pragmatic clinical practice. The Haemorrhoids topic has been updated to recommend that topical preparations for haemorrhoids which should be purchased over the counter in line with NHS Clinical Commissioners (2018). And the Pancreatitis - chronic topic has been updated in line with NICE guidance.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - August 2021' on Email Share 'CKS Updates - August 2021' on Delicious Share 'CKS Updates - August 2021' on Digg Share 'CKS Updates - August 2021' on Facebook Share 'CKS Updates - August 2021' on reddit Share 'CKS Updates - August 2021' on Twitter

NICE Guidance - August 2021

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of August 2021. This month are five guidelines and one COVID-19 rapid guideline that impact upon primary care.

The Bronchiolitis in children: diagnosis and management guideline has been updated. It covers diagnosing and managing bronchiolitis in babies and children. It aims to help healthcare professionals diagnose bronchiolitis and identify if babies and children should be cared for at home or in hospital. The update reviewed the evidence and updated the recommendations on oxygen saturation thresholds for referral to hospital.

The Antenatal care guideline has been published. It covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check‑ups, information and support.

The Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s guideline has been published. It covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD-OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.

The Babies, children and young people's experience of healthcare guideline has been published. It describes good patient experience for babies, children and young people, and makes recommendations on how it can be delivered. It aims to make sure that all babies, children and young people using NHS services have the best possible experience of care.

The Chronic kidney disease: assessment and management guideline has been published, replacing previous guidelines. It covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with chronic kidney disease.

The COVID-19 rapid guideline: managing COVID-19 guideline has been updated. The update corrects an error in the recommended dose of prednisolone for children with a greater than 44-week corrected gestational age.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - August 2021' on Email Share 'NICE Guidance - August 2021' on Delicious Share 'NICE Guidance - August 2021' on Digg Share 'NICE Guidance - August 2021' on Facebook Share 'NICE Guidance - August 2021' on reddit Share 'NICE Guidance - August 2021' on Twitter

CKS Updates - July 2021

During July 2021 Clinical Knowledge Summaries were updated in the following areas.

All topics have been reviewed and updated in keeping with current guidance with minor layout changes. The two Contraception topics have been updated to remove retired Quality and Outcomes Framework (QOF) indicators. The Pancreatitis - acute topic has been updated in line with the NICE guideline on Pancreatitis.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - July 2021' on Email Share 'CKS Updates - July 2021' on Delicious Share 'CKS Updates - July 2021' on Digg Share 'CKS Updates - July 2021' on Facebook Share 'CKS Updates - July 2021' on reddit Share 'CKS Updates - July 2021' on Twitter

NICE Guidance - July 2021

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of July 2021. This month are two guidelines, four technology appraisals and one COVID-19 rapid guideline that impact upon primary care.

The Type 1 diabetes in adults: diagnosis and management guideline has been updated. It covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications. This updated amended the recommendations on long-acting insulin therapy.

The Clostridioides difficile infection: antimicrobial prescribing guideline has been published. It sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance.

The Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation technology appraisal has been updated. This update amended recommendation 1.2 to include consideration of the risks and benefits of this and other anticoagulants approved by NICE.

The Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation technology appraisal has been updated. This update amended recommendation 1.2 to include consideration of the risks and benefits of this and other anticoagulants approved by NICE.

The Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation technology appraisal has been updated. This update amended recommendation 1.2 to include consideration of the risks and benefits of this and other anticoagulants approved by NICE.

The Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation technology appraisal has been updated. This update amended recommendation 1.2 to include consideration of the risks and benefits of this and other anticoagulants approved by NICE.

The COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) guideline has been published. It covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. There is limited evidence available to inform clinical management, identification and management of the condition is evolving quickly as the case definition becomes clearer. This guideline was produced to support clinicians to diagnose and manage this newly recognised syndrome.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - July 2021' on Email Share 'NICE Guidance - July 2021' on Delicious Share 'NICE Guidance - July 2021' on Digg Share 'NICE Guidance - July 2021' on Facebook Share 'NICE Guidance - July 2021' on reddit Share 'NICE Guidance - July 2021' on Twitter

« Older Posts Newer Posts »

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.

vipers